Endoperoxidation, hyperprostaglandinemia, and hyperlipidemia in a case of erythrophagocytic lymphohistiocytosis. Reversal with VP‐16 and indomethacin

R. E. Brown, W. P. Bowman, C. A. D'Cruzmd, T. E. Pick, J. E. Champion

Research output: Contribution to journalArticle

20 Scopus citations

Abstract

Clinicopathologic and histopathologic evidence of both endoperoxidation with hyperprostaglandinemia and hyperlipidemia in a 5‐week‐old infant with a hemophagocytic syndrome is reported. Institution of histiocytolytic (VP‐16) and cyclo‐oxygenase inhibitor (indomethacin) therapies returned the prostaglandin levels and lipid profile to a nearly normal state coincidental with clinical recovery. It appears that by reducing the cell mass of histiocytes and controlling the over‐production of prostaglandins, some types of hemophagocytic syndrome can be reversed.

Original languageEnglish
Pages (from-to)2388-2393
Number of pages6
JournalCancer
Volume60
Issue number10
DOIs
StatePublished - 15 Nov 1987

Fingerprint Dive into the research topics of 'Endoperoxidation, hyperprostaglandinemia, and hyperlipidemia in a case of erythrophagocytic lymphohistiocytosis. Reversal with VP‐16 and indomethacin'. Together they form a unique fingerprint.

  • Cite this